Graphene has emerged as a 2D material with interesting physical properties.\(^1\)\(^2\) Intensive research is ongoing to investigate the quantum physics in this system and potential applications for nanoelectronic devices,\(^3\) transparent conductors, and nanocomposite materials.\(^3\) Thus far, little has been done to explore graphene in biological systems, despite much effort in the area of carbon nanotubes for in vitro and in vivo biological applications.\(^4\)\(^5\) Here, we synthesize and functionalize nanoscale graphene oxide (NGO) sheets (<50 nm) by branched, biocompatible polyethylene glycol (PEG) to render high aqueous solubility and stability in physiological solutions including serum. We then uncover a unique ability of graphene in the attachment and delivery of aromatic, water insoluble drugs.

It is known that clinical use of various potent, hydrophobic molecules (many of them aromatic) is often hampered by their poor water solubility. Although synthesis of water soluble prodrugs may circumvent the problem, the efficacy of the drug decreases. Here, we show that PEGylated NGO (NGO–PEG) readily complexes with a water insoluble aromatic molecule SN38, a camptothecin (CPT) analogue,\(^10\) via noncovalent van der Waals interaction. The NGO–PEG–SN38 complex exhibits excellent aqueous solubility and retains the high potency of free SN38 dissolved in organic solvents. The toxicity exceeds that of irinotecan (CPT-11, a FDA approved SN38 analogue),\(^10\) via noncovalent van der Waals interaction. The NGO–PEG–SN38 complex exhibits excellent aqueous solubility and retains the high potency of free SN38 dissolved in organic solvents. The toxicity exceeds that of irinotecan (CPT-11, a FDA approved SN38 analogue),\(^10\) via noncovalent van der Waals interaction. The NGO–PEG–SN38 complex exhibits excellent aqueous solubility and retains the high potency of free SN38 dissolved in organic solvents. The toxicity exceeds that of irinotecan (CPT-11, a FDA approved SN38 analogue),\(^10\) via noncovalent van der Waals interaction. The NGO–PEG–SN38 complex exhibits excellent aqueous solubility and retains the high potency of free SN38 dissolved in organic solvents. The toxicity exceeds that of irinotecan (CPT-11, a FDA approved SN38 analogue),\(^10\) via noncovalent van der Waals interaction. The NGO–PEG–SN38 complex exhibits excellent aqueous solubility and retains the high potency of free SN38 dissolved in organic solvents. The toxicity exceeds that of irinotecan (CPT-11, a FDA approved SN38 analogue),\(^10\) via noncovalent van der Waals interaction. The NGO–PEG–SN38 complex exhibits excellent aqueous solubility and retains the high potency of free SN38 dissolved in organic solvents. The toxicity exceeds that of irinotecan (CPT-11, a FDA approved SN38 analogue),\(^10\) via noncovalent van der Waals interaction. The NGO–PEG–SN38 complex exhibits excellent aqueous solubility and retains the high potency of free SN38 dissolved in organic solvents. The toxicity exceeds that of irinotecan (CPT-11, a FDA approved SN38 analogue),\(^10\) via noncovalent van der Waals interaction. The NGO–PEG–SN38 complex exhibits excellent aqueous solubility and retains the high potency of free SN38 dissolved in organic solvents. The toxicity exceeds that of irinotecan (CPT-11, a FDA approved SN38 analogue),\(^10\) via noncovalent van der Waals interaction. The NGO–PEG–SN38 complex exhibits excellent aqueous solubility and retains the high potency of free SN38 dissolved in organic solvents. The toxicity exceeds that of irinotecan (CPT-11, a FDA approved SN38 analogue),\(^10\) via noncovalent van der Waals interaction. The NGO–PEG–SN38 complex exhibits excellent aqueous solubility and retains the high potency of free SN38 dissolved in organic solvents. The toxicity exceeds that of irinotecan (CPT-11, a FDA approved SN38 analogue),\(^10\) via noncovalent van der Waals interaction. The NGO–PEG–SN38 complex exhibits excellent aqueous solubility and retains the high potency of free SN38 dissolved in organic solvents. The toxicity exceeds that of irinotecan (CPT-11, a FDA approved SN38 analogue),\(^10\) via noncovalent van der Waals interaction. The NGO–PEG–SN38 complex exhibits excellent aqueous solubility and retains the high potency of free SN38 dissolved in organic solvents. The toxicity exceeds that of irinotecan (CPT-11, a FDA approved SN38 analogue),\(^10\) via noncovalent van der Waals interaction. The NGO–PEG–SN38 complex exhibits excellent aqueous solubility and retains the high potency of free SN38 dissolved in organic solvents. The toxicity exceeds that of irinotecan (CPT-11, a FDA approved SN38 analogue),\(^10\) via noncovalent van der Waals interaction.

We then investigated the binding of SN38 to NGO–PEG. We chose SN38 as a cargo because SN38 is a potent topoisomerase I inhibitor.\(^10\) To be active, CPT-11 currently used in clinic has to be metabolized to SN38 after systematic administration.\(^10\)\(^13\) However a large amount of CPT-11 is excreted before transforming to SN38 or metabolized to other inactive compounds.\(^14\) The water insolubility has prevented the direct use of SN38 in the clinic.\(^10\)

We found that SN38 was complexed with NGO–PEG (Figure 2a) by simple mixing of SN38 dissolved in DMSO with a NGO–PEG water solution. The excess, uncoupled SN38 precipitated and was removed by centrifugation. Repeated washing and filtration were used to remove DMSO and any residual free SN38 (see SI for details). UV–vis spectrum of the resulting solution revealed SN38 peaks superimposing with the absorption curve of NGO–PEG (Figure 2b), suggesting loading of SN38 onto NGO–PEG. On the basis of the extinction coefficients, we estimated that 1 g of NGO–PEG loaded ∼0.1 g of SN38 (SI). An increase in sheet thickness was observed after SN38 loading on NGO–PEG (SI Figure S3). A control experiment revealed no loading of SN38 on PEG polymer in a solution free of NGO.

Unlike free SN38, which was very insoluble in water, NGO–PEG–SN38 complexes were water soluble at concentrations up to ∼1 mg/mL (in terms of SN38). Fluorescence spectra of NGO–PEG–SN38 and free SN38 at the same SN38 concentration showed drastic fluorescence quenching of SN38 in the NGO–PEG–SN38 case (Figure 2c), suggesting close proximity of SN38 to the NGO sheets. We suggest that the binding of SN38 onto NGO–PEG was noncovalent in nature, driven by hydrophobic interactions and π–π stacking\(^15\)\(^16\) between SN38 and aromatic regions of the graphene oxide sheets. The existence of aromatic conjugated domains on GO was revealed by NMR previously.\(^17\)

To determine the stability of SN38 loaded on NGO–PEG and release rate, we incubated NGO–PEG in phosphate buffer saline (PBS) and mouse serum respectively at 37 °C and measured the percentage of retained SN38 on NGO–PEG (Figure 2d, see SI for experimental details). We found that SN38 on NGO–PEG exhibited negligible release from NGO in PBS and ∼30% release in serum in 3 days (Figure 2d). This suggested strong noncovalent binding of SN38 on graphene oxide sheets. The slow but finite release of SN38 in serum was likely caused by the binding of SN38 by serum proteins.\(^18\)

MTS assay found that NGO–PEG–SN38 afforded highly potent cancer cell killing in vitro with a human colon cancer cell line HCT-
and NGO untreated control) data of HCT-116 cells incubated with CPT-11, SN38, and NGO—PEG—SN38. The SN38 absorbance at 380 nm was used to determine the loading.

Figure 3. Our water soluble NGO—PEG—SN38 exhibited high potency with IC50 values of ∼6 nM for HCT-116 cells, which is 1000-fold more potent than CPT-11 and similar to that of free SN38 dissolved in DMSO (Figure 3a). The high potency of NGO—PEG—SN38 was also observed with various other cancer cell lines tested (SI Table S1). Importantly, no obvious toxicity was measured for various concentrations of plain NGO—PEG without drug loading (Figure 3b), suggesting that the PEGylated nanographene oxide sheets were not cytotoxic by themselves. Apoptosis assay further confirmed no obvious increase of cell death or apoptosis after incubating cells with plain NGO—PEG (SI Figure S4). The cellular uptake of NGO—PEG was likely via endocytosis as evidenced by confocal fluorescence microscopy data (SI Figure S5).

We found that the strategy of attaching various types of insoluble, aromatic drug molecules onto NGO—PEG via simple adsorption was general. Other drugs that we succeeded in loading onto NGO—PEG by simple adsorption included different camptothecin analogues and Iressa (gefitinib), a potent epidermal growth factor receptor (EGFR) inhibitor (SI Figures S6 and S7).

The water soluble NGO—PEG—SN38 complex could open up a window to potential use of this drug. Graphitic nanocarriers including nanographene sheets and carbon nanotubes afford strong noncovalent binding with aromatic drugs via simple adsorption.16 Graphene sheets as drug carrier are interesting because both sides of a single sheet could be accessible for drug binding. The unique 2D shape and ultrasmall size (down to 5 nm) of NGO—PEG may offer interesting in vitro and in vivo behaviors. Moreover, the low cost and large production scale of graphite and GO is unmatched by carbon nanotubes. Thus the biocompatible nanographene sheets are novel materials promising for biological applications.

Acknowledgment. This work was partly supported by NIH-NCI CCNE-TR, a Stanford BioX Grant, and a Stanford graduate fellowship.

Supporting Information Available: Experimental details and other supplementary data. This material is available free of charge via the Internet at http://pubs.acs.org.

References
(1) Geim, A. K.; Novoselov, K. S. Nat. Mater. 2007, 6, 183–191.
(2) Li, X. L.; Wang, X. R.; Zhang, L.; Lee, S. W.; Dai, H. J. Science 2008, 319, 1229–1232.
(3) Stankovich, S.; Dikin, D. A.; Dommett, G. H. B.; Kohlhaas, K. M.; Zimney, E. J.; Stach, E. A.; Piner, R. D.; Nguyen, S. T.; Ruoff, R. S. Nature 2006, 442, 282–286.
(4) Kam, N. W. S.; Jessop, T. C.; Wender, P. A.; Dai, H. J. Am. Chem. Soc. 2004, 126, 6850–6851.
(5) Kam, N. W. S.; O’Connell, M.; Wisdom, J. A.; Dai, H. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 11600–11605.
(6) Liu, Z.; Cai, W. B.; He, L. N.; Nakayama, N.; Chen, K.; Sun, X. M.; Chen, X. Y.; Dai, H. J. Nat. Nanotechnol. 2007, 2, 47–52.
(7) Liu, Z.; Davis, C.; Cai, W.; He, L.; Chen, X.; Dai, H. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 1410–1415.
(8) Chenkuri, P.; Gannon, C. J.; Leeuw, T. K.; Schmidt, H. K.; Smalley, R. E.; Curley, S. A.; Weisman, R. B. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 18882–18886.
(9) Peazzell, R. P.; Nakayama-Ratchford, N.; Dai, H.; Lippard, S. J. Am. Chem. Soc. 2007, 129, 8438–8439.
(10) Tanizawa, A.; Fujimori, A.; Fujimori, Y.; Pommier, Y. J. Natl. Cancer Inst. 1994, 86, 836–842.
(11) Huynh, W. S.; Offeman, R. E. J. Am. Chem. Soc. 1958, 80, 1339–1339.
(12) Kam, N. W. S.; Dai, H. J. Am. Chem. Soc. 2005, 127, 6021–6026.
(13) Kawato, Y.; Aonuma, M.; Hirota, Y.; Kuga, H.; Sato, K. J. Cancer Res. Clin. Oncol. 1991, 117, 4187–4191.
(14) Slatter, G. J.; Schaaf, L. J.; Sams, J. P.; Feenstra, K. L.; Johnson, M. G.; Bombardt, P. A.; Cathcart, K. S.; Verburg, M. T.; Pearson, L. K.; Compton, L. D.; Miller, L. L.; Baker, D. S.; Pesheck, C. V.; Lord, R. S. Drug Metab. Dispos. 2000, 28, 423–433.
(15) Chen, R.; Zhang, Y.; Wang, D.; Dai, H. J. Am. Chem. Soc. 2001, 123, 3838–3839.
(16) Liu, Z.; Sun, X.; Nakayama, N.; Dai, H. ACS Nano 2007, 1, 50–56.
(17) Lerf, A.; He, H. Y.; Forster, M.; Klinowski, J. J. Phys. Chem. B 1998, 102, 4477–4482.
(18) Burke, T. G.; Mi, Z. H. J. Med. Chem. 1994, 37, 40–46.

J. AM. CHEM. SOC. • VOL. 130, NO. 33, 2008 10877